Fresh data on protein interactions in Alzheimer’s disease

2 Jul 2019

Demonstrates the unique ability of diffusional sizing to assess protein binding in-solution and for difficult-to-study systems.

Fluidic Analytics’ diffusional sizing technology has been influential in a recent study that investigates protein binding and self-assembly in Alzheimer’s disease. This work will be presented by Professor Sara Linse of Lund University, Sweden, during the FEBS/EMBO Women in Science Award plenary lecture at FEBS 2019, Krakow, Poland (Sunday 7 July at 2 pm). Her work on the mechanism of amyloid β aggregation and the role of inhibitors demonstrates the unique ability of diffusional sizing to assess protein binding in-solution and for difficult-to-study systems.

Fresh data on protein interactions in Alzheimer’s disease
Professor Sara Linse will highlight the Fluidity One-W as an influential technology for protein interaction analysis during plenary lecture at FEBS 2019.

Fluidic Analytics will host an extended Q&A session with Professor Linse at their booth (number 7) at 3 pm following her plenary talk. Visitors to the Fluidic Analytics booth will also be able to have an early look at the Fluidity One-W before its official launch later this year. This instrument has the ability to assess on-target protein interactions in solution and in crude biological backgrounds – opening up the possibilities for detailed analysis of proteins in their near-native states and natural environments. The system is easy-to-use, and based on the well-understood relationship between size and diffusion rate, providing researchers with true confidence in the quality and accuracy of their data.

Professor Sara Linse, Department of Biochemistry and Structural Biology, Lund University commented: “During our research into protein amyloid formation, we have used many different techniques for assessing protein interactions – all with different limitations and advantages. With diffusional sizing, we were able to confidently generate accurate and complete in-solution data using amyloid proteins to connect stoichiometry and binding affinities with protein self-assembly. The data we will present at FEBS 2019 could provide key insights for novel therapeutic approaches in Alzheimer’s disease. The Fluidity One-W has contributed significantly to this detailed understanding.”

With applications ranging from neurobiology and cell signalling to drug discovery, the potential impact of diffusional sizing in fundamental scientific research is vast and spans many research areas. Dr Sean Devenish, Head of R&D at Fluidic Analytics explained: “The unique capabilities of the Fluidity One-W position it as the only viable option for analysing difficult-to-study proteins, like amyloid fibrils, in solution. Researchers gain the best insight into what their protein of interest is interacting with, and how, even in complex backgrounds such as crude lysates. The technology is opening up many new avenues of research into protein interactions and expanding the systems that can be studied, and Professor Linse’s recent work is a great example of what’s possible with this new approach to protein analysis.”

Read More

Related news

Eisai collaborates with University of Dundee on cancer drug discovery

Eisai collaborates with University of Dundee on cancer drug discovery

10 Jul 2019

It is hoped that research into PROTACs will lead to new drug discoveries for proteins present in cancer, which are difficult to treat with conventional small molecule inhibitors.

Read more 
Cyclolab Ltd strengthens its position in the market

Cyclolab Ltd strengthens its position in the market

1 Jul 2019

Cyclolab Ltd. is an R&D and cGMP manufacturing company focusing on all aspects of cyclodextrin science, manufacturing and applications for cyclodextrin, Dexolve, Sugammadex, formulation development, custom synthesis, Niemann Pick C.

Read more 
Inaugural Bio Integrates conference highlights industry's inefficiency in developing products

Inaugural Bio Integrates conference highlights industry's inefficiency in developing products

18 Jun 2019

Industry leaders give voice to issues and trends shaping the biotech sector, including the importance of collaboration.

Read more 
Clinical supply milestone reached for triple-negative breast cancer treatment

Clinical supply milestone reached for triple-negative breast cancer treatment

12 Jun 2019

PhoenixMD and WuXi STA have produced a multikilogram drug supply for PMD-026 under GMP manufacturing practices.

Read more 
Trial finds vitamin D does not prevent type 2 diabetes in people at high risk

Trial finds vitamin D does not prevent type 2 diabetes in people at high risk

11 Jun 2019

No meaningful difference between the two study groups regardless of age, sex, race or ethnicity.

Read more 
Partnership seeks breath biomarkers for the early detection of malignant mesothelioma

Partnership seeks breath biomarkers for the early detection of malignant mesothelioma

6 Jun 2019

Owlstone Medical and IAHFIAW to use Breath Biopsy to examine the chemicals found on the breath of individuals with documented historical exposure to asbestos and radiologically and histologically confirmed mesothelioma.

Read more 
Lilly gets its hands on non-opioid pain asset

Lilly gets its hands on non-opioid pain asset

4 Jun 2019

Early-phase molecule from Centrexion to be developed further as a potential non-opioid treatment option for multiple pain conditions.

Read more 
Updated clinical trial simulation software saves time and money

Updated clinical trial simulation software saves time and money

3 Jun 2019

One customer saves $25m and 3 years' development time in their clinical development strategy.

Read more 
Merck bolsters oncology pipeline with acquisition

Merck bolsters oncology pipeline with acquisition

22 May 2019

Acquisition includes novel late-stage renal cell carcinoma candidate, PT2977.

Read more 
Follicum files patent application for new topical formulation for hair loss

Follicum files patent application for new topical formulation for hair loss

30 Apr 2019

Using easy-to-apply cream instead of direct scalp injection would extend patent protection by 8 years.

Read more